Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities

Imtiaz Ahmad, Mohammud Alam, Ryan Saadi, Saborny Mahmud, Emily Saadi
doi: https://doi.org/10.1101/2020.05.18.20066902

Article Information

doi 
https://doi.org/10.1101/2020.05.18.20066902
History 
  • May 22, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Imtiaz Ahmad, MD, MPH, FCCP1,*,
  2. Mohammud Alam, MD2,
  3. Ryan Saadi, MD, MPH3,6,
  4. Saborny Mahmud4 and
  5. Emily Saadi, BS5
  1. 1Allergy, Sleep & Lung Care, 21st Century Oncology, Fort Myers, FL
  2. 2Infectious Disease Specialist, Cordial Medical PC, Farmingdale, NY
  3. 3Center for Market Access and Medical Innovation, Warren, NJ
  4. 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
  5. 5Yale University, School of Public Health, New Haven, CT
  6. 6Quantaira Health, New York, NY
  1. ↵*Corresponding author: Imtiaz Ahmad, MD, Allergy, Sleep & Lung Care, 21st Century Oncology, Fort Myers, FL. email: iahmad02017{at}gmail.com
Back to top
Posted May 22, 2020.
Download PDF
Data/Code
Email
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities
Imtiaz Ahmad, Mohammud Alam, Ryan Saadi, Saborny Mahmud, Emily Saadi
medRxiv 2020.05.18.20066902; doi: https://doi.org/10.1101/2020.05.18.20066902
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area